ABOUT US

Our Story Investigating neurodegenerative diseases from a different perspective. Read more Management team Read more Board of directors Our board of directors is composed of leading investors and independent members.…Continue readingABOUT US

Research & Development

Discovery at MedDay Our metabolomics platform, SPECMET, has the ability to identify specific metabolic signatures in major central nervous system disorders, providing numerous opportunities for further pipeline development. By focusing…Continue readingResearch & Development

For Patients and Families

At MedDay, our guiding principle is focusing on the needs and outcomes of our patients, particularly those living with neurodegenerative diseases. Their welfare, and that of their families, is at…Continue readingFor Patients and Families

Medday Pharma – Dare to Explore

Alzheimer’s Disease

Alzheimer’s disease (AD) is the most common form of dementia. There is no treatment to stop disease progression or slow it down. Thus patient care continues to be based on…Continue readingAlzheimer’s Disease

Medical information request

Name* Surname* Company or Institution Address City Country* Email* Phone Message* Privacy Policy* Privacy Policy You have answered a questionnaire and provided us with information that may qualify as personal.…Continue readingMedical information request

For Healthcare Professionals

Terms of use This section is intended for healthcare professionals only. If you are a healthcare professional, please select ‘continue’. If you are not a healthcare professional, please navigate back…Continue readingFor Healthcare Professionals

Committed to patients, our passionate teams are investigating brain metabolism therapies, utilizing an innovative approach, with the goal of transforming the lives of people affected by serious neurodegenerative conditions.

CAREERS

MD1105

MD1105 is being developed as a disease-modifying therapy in Alzheimer’s disease (undisclosed molecule and mechanism of action). While currently in the pre-clinical phase, MedDay anticipates entering the clinic in early…Continue readingMD1105

Our story

  The story of MedDay began in 2011, when Frédéric Sedel, MD, PhD, a neurologist and neuroscientist met with Guillaume Brion, an entrepreneur with experience in drug development. Both used…Continue readingOur story

For Patients and Families

At MedDay, our guiding principle is focusing on the needs and outcomes of our patients, particularly those living with neurodegenerative diseases. Their welfare, and that of their families, is at…Continue readingFor Patients and Families

Our Discovery Development Story

MD1003 is a highly-concentrated pharmaceutical-grade biotin (vitamin H). The dosage is 300 mg/day corresponding to 10,000 times the recommended daily intake of biotin. As such, MD1003 is no longer a…Continue readingOur Discovery Development Story